Gelonghui May 30丨Tonghua Jinma (000766.SZ) held a performance briefing on May 29, 2024 to discuss “Can new drug submissions be detected as soon as possible at the Drug Evaluation Center of the State Drug Administration?” The company replied that the company's new drug, amber octahydroaminoacridine tablets, has now completed the investigation, statistical analysis report, and clinical trial summary report. The next step is to submit a marketing application for the new drug to CDE. Currently, in accordance with CDE related requirements, the company is proceeding normally according to the established work plan.
通化金马(000766.SZ)：新药琥珀八氢氨吖啶片现已完成揭盲、统计分析报告与临床试验总结报告
Tonghua Jinma (000766.SZ): The new drug amber octahydroaminoacridine tablets have now completed investigation, statistical analysis reports and clinical trial summary reports
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.